U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 14

1.

Epigenetic reprogramming in relapsed childhood ALL

(Submitter supplied) Reversing gene expression signatures in relapsed patient may restore chemosensitivity. We demonstrate that the histone deacetylase inhibitor vorinostat not only reprograms the aberrant gene expression profile of relapsed blasts but is synergistic when applied prior to chemotherapy in primary patient samples and leukemia cell lines
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
14 Samples
Download data: CEL
Series
Accession:
GSE34880
ID:
200034880
2.

Combination of HDAC inhibitors and Azacytidine for Cancer Cell Selective Targeting of Esophageal Cancer Cells

(Submitter supplied) Esophageal cancers (ECs) are highly aggressive tumors with poor prognosis and few treatment options. This study investigated the possibility of treating esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) cells by inhibitors of broad and specific histone deacetylases (HDACi; SAHA, MS-275, FK228) and/or of DNMT (Azacytidine, AZA). Drug targets (HDAC1,2,3 and DNMT1) were present in non-neoplastic (HET-1A), ESCC (OE21) and EAC (OE33) cell lines. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL10558
36 Samples
Download data: TXT
Series
Accession:
GSE57130
ID:
200057130
3.

Promoter hypermethylation in MLL-r leukemia: biology and therapeutic targeting

(Submitter supplied) MLL-r infant acute lymphoblastic leukemia (ALL) has largely unclear oncogenesis. It has been shown unrelated to copy number change or mutations in the tyrosine kinome. We therefore, explored the possible role of genome wide CpG island hypermethylation in MLL-r infant ALL. We employed the HpaII-tiny fragment Enrichment by Ligation-mediated PCR (HELP) assay to examine MLL-r infant leukemia samples (n=5), other common childhood ALL (n=5) and normals (n=5). more...
Organism:
Homo sapiens
Type:
Methylation profiling by genome tiling array
Platform:
GPL6604
15 Samples
Download data: PAIR
Series
Accession:
GSE19671
ID:
200019671
4.

HDACI and DAC induce specific epigenetic profile in DLBCL

(Submitter supplied) Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoid neoplasm in the world representing 30-40% of all lymphomas. Standard immunochemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) ensures cure in 60 to 65% of patients, while the rest progress or relapse. While advances have been made in the treatment of DLBCL, especially with the addition of rituximab, it is now apparent that there may be significant differences in prognosis that are related to the cell of origin, and that this disease is heterogeneous and novel treatment options are needed. more...
Organism:
Homo sapiens
Type:
Expression profiling by array; Methylation profiling by array
Dataset:
GDS4006
Platforms:
GPL8490 GPL6947
24 Samples
Download data: TXT
Series
Accession:
GSE27226
ID:
200027226
5.
Full record GDS4006

Histone deacetylase inhibitor and hypomethylating agent effect on diffuse large B-cell lymphoma cell lines

Analysis of three large B-cell lymphoma cell lines treated with the histone deacetylase inhibitor panobinostat, hypomethylating agent decitabine, or both for 48hrs. Panobinostat synergizes with decitabine in DLBCL cells. Results provide insight into the molecular basis for this synergistic effect.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 4 agent, 3 cell line sets
Platform:
GPL6947
Series:
GSE27226
12 Samples
Download data
6.

Gene expression profiles of MV-4-11 AML cells treated HDAC1/2 -selective inhibitor and Azacitidine

(Submitter supplied) Determine the differences in gene expression profiles of MV-4-11 AML cells treated with HDAC1/2-selective inhibition, azacitidine, or the combination of the two agents. Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells. Outcomes for patients with AML remain poor, highlighting the need for novel treatment options. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL15207
4 Samples
Download data: CEL
Series
Accession:
GSE84440
ID:
200084440
7.

Gene expression profiles of Hodgkin’s lymphoma cells after treatment with vorinostat

(Submitter supplied) By using high-density DNA microarrays, we analyzed the gene-expression profile of Hodgkin's lymphoma cell line L-540 after tretament with the histone deactelyse inhibitor vorinostat. Kewitz et al., submitted
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL96
2 Samples
Download data: CEL
Series
Accession:
GSE30884
ID:
200030884
8.

Analysis of genome-wide methylation and gene expression induced by decitabine treatment in HL60 leukemia cell line

(Submitter supplied) Epigenetic changes play a role in the pathogenesis of myeloid malignancies and hypomethylating agents have shown efficacy in these diseases. We studied the apoptotic effect, the genome-wide methylation and gene expression profiles in HL60 cells following decitabine treatment, using micro-array technologies. Decitabine treatment resulted in a decrease in global DNA methylation, corresponding to 4876 probeset IDs with significantly reduced methylation levels, while expression of 2583 IDs was induced. more...
Organism:
Homo sapiens
Type:
Expression profiling by array; Methylation profiling by genome tiling array
Platforms:
GPL570 GPL5082
12 Samples
Download data: CEL, TXT
Series
Accession:
GSE24224
ID:
200024224
9.

Differential gene expression analysis of pediatric acute myeloid leukemia cell lines treated with azacytidine and panobinostat alone or in combination and compared to vehicle treated cells.

(Submitter supplied) Pediatric AML cell lines (MV4;11, AML-193 and THP-1) were treated with DNA hypomethylating agent (azacytidine) and a pan histone deactylase inhibitor (panobinostat) alone or in combination. Treatment of AML cell lines with these epigenetic drugs synergistically suppresses cell viability in vitro and in xenograft models in vivo. Data show differential regulation of gene expression in AML cell lines by epigenetic drugs at concentrations which retained cell viability at a minimum of 75% even in the combination treatment.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL16686
60 Samples
Download data: CEL, CHP
Series
Accession:
GSE83983
ID:
200083983
10.

ChIP-on-chip from acute myeloid leukemia cell lines and clinical samples for H3K4me3, H3K27me3, and EZH2

(Submitter supplied) Histone modifcations at the p15INK4b gene were compared in sample with p15INK4b DNA methylation vs. samples with no DNA methylation AML clinical samples without DNA methylation exhibit bivalent histone modifications at p15INK4b, while clinical samples with DNA methylation display lower H3K4me3 and retain H3K27me3
Organism:
Homo sapiens
Type:
Genome binding/occupancy profiling by genome tiling array
Platform:
GPL8754
40 Samples
Download data: TXT
Series
Accession:
GSE16730
ID:
200016730
11.

Integrated Genomic Analysis of Relapsed Childhood Acute Lymphoblastic Leukemia reveals therapeutic strategies

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by array; Methylation profiling by array
Platforms:
GPL570 GPL8490
166 Samples
Download data: CEL
Series
Accession:
GSE28462
ID:
200028462
12.

Promoter methylation data from ALL diagnosis and relapse pediatric acute lymphoblastic leukemia cases

(Submitter supplied) Relapse samples have high methylation level than dianosis samples
Organism:
Homo sapiens
Type:
Methylation profiling by array
Platform:
GPL8490
68 Samples
Download data: TXT
Series
Accession:
GSE28461
ID:
200028461
13.

Expression data from ALL diagnosis and relapse pediatric acute lymphoblastic leukemia cases

(Submitter supplied) There is a distinct signature of differentially expressed probes from diagnosis to relapse
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
98 Samples
Download data: CEL
Series
Accession:
GSE28460
ID:
200028460
14.

Identification of relapse mechanisms for pediatric T-ALL (T-cell acute lymphoblastic leukemia) through scRNAseq analysis

(Submitter supplied) If relapses occur in only 20% of T-ALL children, 70% will have a dismal outcome, justifying the need for new therapeutic options. Transcriptomic plasticity is a property of leukemic cells to adapt their functions and resist to treatments. The project aims at analyzing, at a single cell resolution, the variations of the gene expression, between diagnostic and relapse. This will allow identification of relapse-associated genes as potential new targets for future innovative treatments.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL18573
3 Samples
Download data: H5
Series
Accession:
GSE262271
ID:
200262271
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=8|qty=2|blobid=MCID_6686873549fc8a2325112583|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Support Center